Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.43 |
| ▸ | LIPE | Q05469 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.42 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27158271 | 0.85 | CHRNB2 (0.46) | CHRNA7LIPECHRNB2CHRNA4SCN9A | |
| SCHEMBL27158705 | 0.85 | CHRNB2 (0.46) | CHRNA7LIPECHRNB2CHRNA4SCN9A | |
| SCHEMBL27158707 | 0.85 | CHRNB2 (0.46) | CHRNA7LIPECHRNB2CHRNA4SCN9A | |
| SCHEMBL25398801 | 0.84 | JAK3 (0.43) | GPR119JAK3CHRNB2CHRNA4 | |
| SCHEMBL29913093 | 0.84 | JAK3 (0.41) | GPR119LIPEJAK3 | |
| SCHEMBL27158533 | 0.83 | GPR119 (0.58) | GPR119 | |
| SCHEMBL30785455 | 0.83 | GPR119 (0.58) | GPR119 | |
| SCHEMBL29912773 | 0.80 | IDH1 (0.44) | GPR119LIPEJAK3 | |
| SCHEMBL29912927 | 0.80 | JAK3 (0.39) | GPR119LIPEJAK3CHRNB2 | |
| SCHEMBL30328612 | 0.79 | GPR119 (0.58) | GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240262832-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2024-08-08 | — | — | US | disclosed |
| EP-4329881-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | Vanqua Bio, Inc. (US) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022232383-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240262832-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | GBA1, GAA, GBA2 | GPR119 101/4885CHRNA7 1356/4885LIPE 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.